{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:22:09Z","timestamp":1782321729161,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012127","name":"Augusta University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012127","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007810","name":"University of North Carolina Wilmington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.anai.2025.01.013","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T11:26:40Z","timestamp":1737372400000},"page":"448-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Randomized, placebo-controlled, phase 1 safety study of oral mucosal immunotherapy in adults with peanut allergy"],"prefix":"10.1016","volume":"134","author":[{"given":"William E.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3362-3720","authenticated-orcid":false,"given":"Nicole","family":"Faris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E.","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anai.2025.01.013_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5630","article-title":"Prevalence and Severity of food allergies among US adults","volume":"2","author":"Gupta","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.anai.2025.01.013_bib0002","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1542\/peds.2011-0204","article-title":"The prevalence, severity, and distribution of childhood food allergy in the United States","volume":"128","author":"Gupta","year":"2011","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.anai.2025.01.013_bib0003","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/all.14666","article-title":"The global burden of illness of peanut allergy. A comprehensive literature review","volume":"76","author":"Leiberman","year":"2021","journal-title":"Allergy"},{"issue":"10322","key":"10.1016\/j.anai.2025.01.013_bib0004","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(21)02390-4","article-title":"Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomized placebo-controlled study","volume":"399","author":"Jones","year":"2022","journal-title":"Lancet"},{"issue":"10207","key":"10.1016\/j.anai.2025.01.013_bib0005","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","article-title":"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomized, double-blind, placebo-controlled, phase 2 study","volume":"394","author":"Chinthrajah","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2025.01.013_bib0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1939-4551-7-6","article-title":"Sublingual immunotherapy: World Allergy Organization position paper 2013 update","volume":"7","author":"Canonica","year":"2014","journal-title":"World Allergy Organ J"},{"issue":"12","key":"10.1016\/j.anai.2025.01.013_bib0007","article-title":"Sublingual immunotherapy for allergic rhinitis","author":"Radulovic","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.anai.2025.01.013_bib0008","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2013.2049","article-title":"Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review","volume":"309","author":"Lin","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.anai.2025.01.013_bib0009","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.2500\/ar.2016.7.0150","article-title":"Oral mucosal immunotherapy for allergic rhinitis: a pilot study","volume":"7","author":"Reisacher","year":"2016","journal-title":"Allergy Rhinol"},{"issue":"6","key":"10.1016\/j.anai.2025.01.013_bib0010","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jaci.2023.01.036","article-title":"Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children","volume":"151","author":"Kim","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.01.013_bib0011","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2019.07.030","article-title":"Long-term sublingual immunotherapy for peanut allergy in children: clinical and immunologic evidence of desensitization","volume":"144","author":"Kim","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.01.013_bib0012","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1398-9995.2007.01611.x","article-title":"Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?","volume":"63","author":"Allam","year":"2008","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2025.01.013_bib0013","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jaci.2010.12.1083","article-title":"Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization","volume":"127","author":"Kim","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.01.013_bib0014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2021.01.003","article-title":"Severity grading system for acute allergic reactions: a multidisciplinary Delphi study","volume":"148","author":"Dribin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"21","key":"10.1016\/j.anai.2025.01.013_bib0015","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy. PALISADE group of clinical investigators","volume":"379","author":"Vickery","year":"2018","journal-title":"N Eng J Med"},{"issue":"7","key":"10.1016\/j.anai.2025.01.013_bib0016","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.jaip.2024.03.014","article-title":"Age-related food aversion and anxiety represent primary patient barriers to food oral immunotherapy","volume":"12","author":"Trevisonno","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10187","key":"10.1016\/j.anai.2025.01.013_bib0017","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(19)30420-9","article-title":"Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety","volume":"393","author":"Chu","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.anai.2025.01.013_bib0018","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jaip.2021.12.022","article-title":"Real-world adoption of FDA-approved peanut oral immunotherapy with Palforzia","volume":"10","author":"Patrawala","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2025.01.013_bib0019","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/1744666X.2024.2315221","article-title":"Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy","volume":"20","author":"Dupont","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2025.01.013_bib0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11882-014-0473-1","article-title":"Immune mechanisms of sublingual immunotherapy","volume":"14","author":"Jay","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/j.anai.2025.01.013_bib0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2023.08.032","article-title":"Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: a randomized, placebo-controlled trial","volume":"153","author":"Kim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"2)(suppl","key":"10.1016\/j.anai.2025.01.013_bib0022","doi-asserted-by":"crossref","first-page":"AB175","DOI":"10.1016\/j.jaci.2016.12.574","article-title":"Sustained unresponsiveness after sublingual immunotherapy for peanut-allergic children","volume":"139","author":"Yang","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.01.013_bib0023","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jaci.2014.11.005","article-title":"A Randomized, Double-Blind, Placebo-Controlled Pilot Study of sublingual versus Oral Immunotherapy for the Treatment of Peanut Allergy","volume":"135","author":"Narisety","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.01.013_bib0024","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0091-6749(97)70203-3","article-title":"Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings","volume":"100","author":"Bagnasco","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.01.013_bib0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40413-015-0063-2","article-title":"Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens","volume":"8","author":"Akdis","year":"2015","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.anai.2025.01.013_bib0026","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacig.2022.05.006","article-title":"OUtMATCH study team. Protocol design and synopsis: omalizumab as monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)","volume":"1","author":"Wood","year":"2022","journal-title":"J Allergy Clin Immunol Glob"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:34:19Z","timestamp":1762364059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1081120625000407"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.01.013","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, placebo-controlled, phase 1 safety study of oral mucosal immunotherapy in adults with peanut allergy","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}